Preparation method and application of silver / silver sulfide nanoprobe for dual diagnosis of endometriosis
By preparing silver/silver sulfide nanoprobes and combining them with MRI and Raman diagnostic techniques, the problems of insufficient resolution and high invasiveness in the diagnosis of endometriosis have been solved, achieving the dual effect of early and accurate diagnosis.
Patent Information
- Application Number
- CN202410640305.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-22
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-05-22
AI Technical Summary
Existing diagnostic techniques for endometriosis suffer from insufficient resolution, high invasiveness, and insensitivity in qualitative analysis, making accurate diagnosis particularly difficult for small or deep lesions.
Silver/silver sulfide nanoprobes were prepared, and retinoic acid was grafted onto them and manganese ions were loaded to construct a dual diagnostic multifunctional nanoprobe. Combined with MRI and Raman diagnostic techniques, high-resolution imaging and spectral analysis of endometriosis were achieved.
It enables early and accurate diagnosis of endometriosis, providing high-resolution MRI images and detailed Raman spectroscopy analysis, improving the accuracy and reliability of diagnosis, and reducing disease progression and complications.
Smart Images

Figure CN118546385B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of nanoprobes, and in particular to a preparation method and application of a silver / silver sulfide nanoprobe for dual diagnosis of endometriosis. Background Art
[0002] Endometriosis is a common chronic gynecological disease characterized by the presence of endometrial glands and stroma outside the uterine cavity, accompanied by chronic inflammation. Endometriosis often causes chronic pelvic pain, infertility, and menstrual disorders, leading to a significant decline in quality of life and seriously affecting women's reproductive health. It is estimated that endometriosis affects 6%-10% of women of childbearing age, and the prevalence of infertile women is about 20%-50%.
[0003] At present, the diagnostic techniques for endometriosis mainly include ultrasound examination and surgical biopsy. Although these techniques can help with diagnosis to a certain extent, there are still some problems and shortcomings in their structure, composition, principles or methods:
[0004] ① Because the size, morphology, and location of endometriosis lesions vary greatly, the resolution and sensitivity of ultrasound examination may not be sufficient to accurately detect all lesions, especially in the case of small local lesions or deep in the pelvis.
[0005] ②Surgical biopsy is a invasive procedure that causes discomfort and risks to patients, and not all patients are suitable for surgery.
[0006] Therefore, it is necessary to explore a new, non-invasive diagnostic method to better meet the diagnostic challenges of endometriosis. Magnetic resonance imaging (MRI), as a non-invasive, radiation-free imaging technology, is increasingly used in clinical diagnosis. Although MRI can provide high-resolution images, it may not be sensitive enough for tiny or early-stage ectopic lesions. In addition, MRI usually requires the use of contrast agents to enhance the abnormal area more clearly, but there is currently no efficient endometriosis-specific contrast agent. Although MRI is effective in locating endometriosis lesions, it is not qualitatively sensitive. There is an urgent need for a diagnostic method that can achieve qualitative results. Raman diagnosis (RSD) is a technology for in vitro diagnosis through Raman spectroscopy. Through the analysis of Raman spectroscopy, detailed information about the chemical composition and molecular structure of the sample can be obtained, which helps to diagnose and evaluate the progression of the disease more accurately. By extracting and culturing endometrial cells from patients with endometriosis and normal endometrial cells in vitro, simulating the separation of endometrial cells from menstrual blood, and synthesizing nanoprobes with targeted ectopic endometrial cells, ectopic endometrial cells showed more obvious Raman spectral signals compared with normal endometrial cells. Secondly, RSD is a non-destructive technology that avoids possible interference factors while retaining the original state of the cells. This gives the technology a significant advantage in studying living tissue samples, allowing real-time observation and analysis without destroying the sample structure. Summary of the invention
[0007] To solve the above problems, the present invention provides a method for preparing a silver / silver sulfide nanoprobe for dual diagnosis of endometriosis and its application. The nanoprobe can not only realize MRI in vivo diagnosis of endometriosis, but also realize Raman diagnosis of endometriosis in vitro, thereby collaboratively diagnosing the occurrence of endometriosis.
[0008] To achieve the above object, the present invention provides a method for preparing a silver / silver sulfide nanoprobe for dual diagnosis of endometriosis, comprising the following steps:
[0009] S1. Silver / silver sulfide Ag / Ag2S-PEI was prepared using silver acetylacetonate and polyethyleneimine as raw materials;
[0010] S2, grafting retinoic acid onto the Ag / Ag2S-PEI prepared in step S1 to prepare a silver / silver sulfide-retinoic acid preparation Ag / Ag2S-RA;
[0011] S3, chelating manganese ions onto the Ag / Ag2S-RA prepared in step S2 to prepare a silver / silver sulfide-retinoic acid chelated manganese ion preparation Ag / Ag2S-Mn@RA;
[0012] S4. Grafting 4-mercaptobenzoic acid onto the Ag / Ag2S-Mn@RA prepared in step S3 to prepare the silver / silver sulfide nanoprobe Ag / Ag2S-Mn@RA-4-MBA.
[0013] Preferably, in step S1, the step of preparing Ag / Ag2S-PEI comprises:
[0014] S1-1, prepare solution A according to the ratio of silver acetylacetonate: trisodium citrate: ethylene glycol = 0.6 mmol: 0.2 mmol: 20 mL;
[0015] 150 mg of polyethyleneimine was added to solution A, and the mixture was reacted for 120 min at room temperature and 800 rpm magnetic stirring to obtain solution B;
[0016] S1-2, adding 1.5 mL of 0.05 M thioacetamide to solution B, reacting for 5 min at room temperature and 800 rpm under magnetic stirring to obtain solution C; adding triethanolamine to solution C, reacting for 5 min at room temperature and 800 rpm under magnetic stirring;
[0017] S1-3. After the reaction is completed, the product is transferred to a microwave synthesizer and maintained at 200°C for 1 hour. The precipitate is then collected by low-temperature centrifugation at 14,000 rpm, 10 min, and 4°C. The precipitate is washed three times with pure water. Finally, the product is dispersed in pure water to obtain Ag / Ag2S-PEI.
[0018] Preferably, the volume ratio of solution A: ethylene glycol solution of polyethyleneimine: thioacetamide: triethanolamine is 3:1:0.3:0.1.
[0019] Preferably, in step S2, the step of preparing the silver / silver sulfide-retinoic acid preparation Ag / Ag2S-RA comprises:
[0020] S2-1, mix retinoic acid and ethanol at a mass volume ratio of 1 mg: 1 mL, add EDC and NHS, and activate at 37°C on a shaker for 1 h;
[0021] S2-2, dissolving the Ag / Ag2S-PEI prepared in step S1 and the solution activated in step S2-1 in anhydrous ethanol at a mass ratio of 5:1, and stirring in an ice bath for 2 h;
[0022] After stirring, the precipitate was collected by centrifugation at 14000 rpm for 10 min, and the precipitate was washed twice with anhydrous ethanol. The final product was dispersed in anhydrous ethanol to obtain Ag / Ag2S-RA.
[0023] Preferably, in step S2-1, the mass ratio of retinoic acid:EDC:NHS is 1:4:4.
[0024] Preferably, in step S3, the preparation of Ag / Ag2S-Mn@RA comprises the following steps:
[0025] S3-1, according to step S2, prepare Ag / Ag2S-RA∶SH-PEG-NH2∶water=1mg∶1mg∶1mL, mix and stir for 6h, and obtain Ag / Ag2S-RA-PEG-NH2 after centrifugation;
[0026] S3-2, re-disperse Ag / Ag2S-RA-PEG-NH2 in water, the pH of the Ag / Ag2S-RA-PEG-NH2 aqueous solution is not less than 7.4; add DOTA-NHS to react for 30 minutes; add MnCl2 and stir to react for 12 hours;
[0027] S3-3. After the reaction is completed, the precipitate is collected by centrifugation at 14000 rpm for 10 min, and the precipitate is washed twice with pure water. The final product is dispersed in pure water to obtain Ag / Ag2S-Mn@RA.
[0028] Preferably, in step S3-2, the mass ratio of DOTA-NHS:MnCl2 is 1:0.2.
[0029] Preferably, the preparation of the silver / silver sulfide nanoprobe includes: dispersing Ag / Ag2S-Mn@RA and 4-mercaptobenzoic acid in anhydrous ethanol according to the mass volume ratio of Ag / Ag2S-Mn@RA:4-mercaptobenzoic acid:anhydrous ethanol prepared in step S3 at a ratio of 0.4 mg:2.18 mg:4 mL, stirring for 12 hours, and centrifuging to obtain Ag / Ag2S-Mn@RA-4-MBA.
[0030] The present invention provides a preparation method and application of a silver / silver sulfide nanoprobe for dual diagnosis of endometriosis, which has the following beneficial effects:
[0031] (1) A dual-diagnostic multifunctional nanoprobe (Ag / Ag2S-Mn@RA / 4-MBA, AMBR) was successfully constructed by grafting retinoic acid on silver / silver sulfide and loading it with manganese ions. This nanoprobe can achieve the ability to target endometriotic lesions in vivo, enabling MRI to achieve excellent T1 imaging capabilities for tiny and deep lesions, providing high-resolution images of endometriosis;
[0032] (2) It can provide images in multiple directions and planes at the same time, so as to comprehensively observe the uterus and nearby tissue structures, help to find the location and range of ectopic lesions, assist in formulating relevant treatment plans and taking timely treatment measures, and reduce the progression of the disease and the occurrence of complications;
[0033] (3) In vitro RSD can provide a detailed analysis of the chemical composition of the sample and help distinguish normal endometrial and ectopic endometrial cells by observing the spectral characteristics, providing important clues for early diagnosis;
[0034] Raman spectroscopy provides microscopic analysis of tissue chemical composition, and MRI provides macroscopic observation of tissue morphology and structure. The two complement each other and can improve the accuracy and reliability of diagnosis;
[0035] The AMBR nanoprobe combines RSD with MRI to achieve early and accurate diagnosis and intervention of endometriosis. It has outstanding effects in diagnosing endometriosis, fills the existing gaps in endometriosis diagnostic technology, and solves the urgent problems in the diagnosis of this disease.
[0036] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 Transmission electron microscopy and mapping diagram of the prepared silver / silver sulfide nanoprobe AMBR;
[0038] Figure 2 Zeta potential analysis diagram of the prepared Ag / Ag2S, AR, AMR and AMBR;
[0039] Figure 3 The figure is the result of the biocompatibility test of AMBR on HUVEC cells;
[0040] Figure 4 Fluorescence inverted microscopy was used to detect the cell uptake of ESCs cells after co-incubation with AMB and AMBR;
[0041] Figure 5 The test results of the prepared AMB and AMBR under a 9.4T small animal imaging instrument; wherein (a) is a nuclear magnetic resonance image, and (b) is a quantitative analysis result of the nuclear magnetic resonance image;
[0042] Figure 6 The figure shows the Raman spectrum test results of the prepared AMBR under infrared light irradiation. DETAILED DESCRIPTION
[0043] In order to make the purpose, technical scheme and advantages disclosed in the embodiments of the present invention clearer, the embodiments of the present invention are further described in detail in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the embodiments of the present invention and are not intended to limit the embodiments of the present invention. Based on the embodiments in this application, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of this application. Examples of the embodiments are shown in the accompanying drawings, where the same or similar reference numerals throughout represent the same or similar elements or elements with the same or similar functions.
[0044] It should be noted that the terms "including" and "having" and any variations thereof are intended to cover non-exclusive inclusions. For example, a process, method, system, product or server that includes a series of steps or units is not necessarily limited to those steps or units explicitly listed, but may include other steps or units that are not explicitly listed or inherent to these processes, methods, products or devices.
[0045] Like reference numerals and letters denote similar items in the following drawings, and thus, once an item is defined in one drawing, further definition and explanation thereof is not required in subsequent drawings.
[0046] Embodiment 1
[0047] Preparation of Ag / Ag2S-PEI:
[0048] 0.6 mmol of silver acetylacetonate and 0.2 mmol of trisodium citrate were dissolved in 15 mL of ethylene glycol to obtain solution A; 150 mg of polyethyleneimine (PEI) was dissolved in 5 mL of ethylene glycol solution to obtain solution B; solution B was added to solution A, and the mixture was reacted at room temperature and 800 rpm magnetic stirring for 120 min.
[0049] 1.5 mL of 0.05 M thioacetamide was added, and the mixture was reacted for 5 min at room temperature and 800 rpm magnetic stirring to obtain solution C. 0.5 mL of triethanolamine was added to solution C, and the mixture was reacted for 5 min at room temperature and 800 rpm magnetic stirring.
[0050] After the reaction, the product was transferred to a microwave synthesizer and kept at 200°C for 1 hour. Finally, the product was collected by low-temperature centrifugation at 14000 rpm, 10 min, and 4°C, and washed with pure water for 3 times. The final product was dispersed in pure water to obtain silver / silver sulfide Ag / Ag2S-PEI.
[0051] Embodiment 2
[0052] Preparation of Ag / Ag2S-PEI grafted retinoic acid (Ag / Ag2S-RA):
[0053] 1 mg of retinoic acid (RA) was dissolved in 1 mL of ethanol, and 4 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and 4 mg of N-hydroxysulfosuccinimide NHS were added, and the mixture was activated on a shaker at 37° C. for 1 h.
[0054] The Ag / Ag2S-PEI synthesized in Example 1 and the activated retinoic acid were dissolved in anhydrous ethanol at a mass ratio of 5:1 and stirred for 2 hours in an ice bath. After stirring, the mixture was collected by centrifugation at 14000 rpm for 10 minutes, washed twice with anhydrous ethanol, and the final product was dispersed in anhydrous ethanol to obtain a silver / silver sulfide-retinoic acid preparation (Ag / Ag2S-RA, abbreviated as AR).
[0055] Embodiment 3
[0056] Preparation of silver / silver sulfide chelated manganese ion (Ag / Ag2S-Mn):
[0057] 2 mg of Ag / Ag2S-PEI prepared in Example 1 and 2 mg of α-mercapto-ω-amino polyethylene glycol (SH-PEG-NH2) were dispersed in 2 mL of water and stirred for 6 h, and then centrifuged to obtain Ag / Ag2S-PEG-NH2. Ag / Ag2S-PEG-NH2 was redispersed in 4 mL of water, 2 mg of (tetraazacyclododecane tetraacetic acid-hydroxysuccinimide ester) DOTA-NHS was added, and the reaction was carried out for 30 min; 0.4 mg of MnCl2 was added, and the mixture was stirred for 12 h.
[0058] After the reaction is completed, the product is collected by centrifugation at 14000 rpm for 10 min, washed twice with pure water, and the final product is dispersed in pure water to obtain a silver / silver sulfide chelated manganese ion preparation (Ag / Ag2S-Mn, abbreviated as AM).
[0059] Embodiment 4
[0060] Preparation of silver / silver sulfide-retinoic acid chelated manganese ion preparation:
[0061] 2 mg of Ag / Ag2S-RA prepared in Example 2 and 2 mg of SH-PEG-NH2 were dispersed in 4 mL of water and stirred for 6 h, and then centrifuged to obtain Ag / Ag2S-RA-PEG-NH2. Ag / Ag2S-RA-PEG-NH2 was redispersed in 4 mL of water, the pH was measured (not less than 7.4), 2 mg of DOTA-NHS was added, and the reaction was continued for 30 min; 0.4 mg of MnCl2 was added, and the mixture was stirred for 12 h.
[0062] After the reaction, the mixture was collected by centrifugation at 14000 rpm for 10 min, washed twice with pure water, and the final product was dispersed in pure water to obtain a silver / silver sulfide-retinoic acid chelated manganese ion preparation (Ag / Ag2S-Mn@RA, abbreviated as AMR).
[0063] Embodiment 5
[0064] Preparation of silver / silver sulfide nanoprobes:
[0065] 0.4 mg of the AMR prepared in Example 4 and 2.18 mg of 4-mercaptobenzoic acid were dispersed in 4 mL of anhydrous ethanol and stirred for 12 h. The mixture was centrifuged to obtain a silver / silver sulfide nanoprobe (Ag / Ag2S-Mn@RA-4-MBA, referred to as AMBR).
[0066] Experimental Testing
[0067] (a) If Figure 1 As shown, an appropriate amount of AMBR was ultrasonically treated and then dripped onto a copper mesh, dried to prepare a transmission electron microscopy sample, and observed using a transmission electron microscope. The prepared AMBR had a janus structure and a particle size of about 20 nm. The results of the nanoprobe elemental spectrum analysis showed that it contained elements such as C, N, O, Ag, S, and Mn.
[0068] (ii) Figure 2 As shown, the potentials of Ag / Ag2S, AR, AMR and AMBR were detected. Since Ag / Ag2S contains a large number of amine groups, it shows a positive charge of about +29 mV. When it is grafted with retinoic acid (RA), the potential drops to +6.5 mV. After chelating manganese ions, the potential drops to -5.5 mV, indicating the successful loading of manganese ions. After grafting 4-mercaptobenzoic acid, the potential drops to -10.5 mV, indicating that the nanoprobe is successfully constructed.
[0069] (III) Figure 3 As shown, the cytotoxic effect of AMBR on normal cells was detected by MTT assay.
[0070] Prepare a 96-well plate and add 1 × 10 4 HUVEC cells were cultured in a 37°C constant temperature incubator containing 5% CO2 for 24 hours. The prepared AMBR preparations were incubated with cells at different concentrations of 0, 20, 40, 80 and 160 μg / mL for 24 hours. The culture medium was removed, and the medium containing MTT was added to each well and cultured for 3.5 hours. The MTT medium was removed, and 150 μL DMSO was added to each well. The purple solid was completely dissolved by shaking on a shaker for 15 minutes, and the absorbance value (OD value) at 490 nm was read using an enzyme marker. The number of live cells was determined based on the measured OD value, and a result graph was drawn.
[0071] The results are as follows Figure 3As shown, with the increase of preparation concentration and drug loading, the survival rate of HUVEC cells was above 80%, indicating that the AMBR nanoprobe has good biocompatibility to normal cells.
[0072] (IV) Figure 4 As shown, the ability of AMB and AMBR to be taken up by primary endometriotic cells was examined using an inverted fluorescence microscope.
[0073] ESCs cells were co-incubated with Cy5.5, AMB-Cy5.5 and AMBR-Cy5.5 for 4 hours (the concentration of each group was 10 μg / mL), and then the uptake of each group by ESCs cells was observed using a fluorescent inverted microscope. The results showed that compared with the Cy5.5 group and the AMB group, the red fluorescence intensity of the AMBR group was the highest, indicating that RB-modified AMBR can be more absorbed by endometriotic cells.
[0074] (V) 8-week-old healthy SD female rats were selected and the autologous endometriosis model was modeled. AMB and AMBR were resuspended in PBS and the above-mentioned nanodrugs were injected into the rats through the tail vein at a drug concentration of 2 mg / kg. 9.4T small animal MRI scans were performed before and 0.25, 0.5, 1, 1.5 and 2 h after drug injection, and then the lesion areas in the images were quantitatively analyzed.
[0075] like Figure 5 As shown in the figure, after the injection of nanomedicine, the image signal-to-noise ratio of the endometriosis lesion area in the AMB and AMBR groups gradually increased over time, reaching a peak at 60 minutes, and then the image signal-to-noise ratio began to decrease. It is worth noting that at the same time point, the image signal-to-noise ratio of the lesion area in the AMBR group was higher than that in the AMB group, further confirming that RB-modified AMBR can better achieve in vivo targeting of endometriosis lesions.
[0076] (VI) Place 400 μg / mL AMBR under a Raman confocal microscope and observe its spectrum under 633 nm infrared light. Figure 6 As shown, AMBR is at 1107 cm -1 、1200cm -1 、1603cm -1 The significant characteristic peaks indicated that AMBR had the potential to diagnose endometriosis in vitro.
[0077] The invention discloses a preparation method of a silver / silver sulfide nanoprobe for dual diagnosis of endometriosis. By grafting retinoic acid on silver / silver sulfide and loading manganese ions, a dual diagnosis multifunctional nanoprobe (AMBR) is successfully constructed. The nanoprobe can achieve the targeting capability of endometriosis lesions in vivo, so that MRI can achieve excellent T1 imaging capability for tiny and deep lesions, and provide high-resolution images of endometriosis; at the same time, images in multiple directions and multiple planes are provided, so as to comprehensively observe the uterus and nearby tissue structures, which is helpful to determine the location and range of ectopic lesions, assist in formulating relevant treatment plans and taking treatment measures in time, and reduce the progression of the disease and the occurrence of complications; the AMBR nanoprobe realizes the early and accurate diagnosis and intervention of endometriosis by the combined application of RSD and MRI, has an outstanding effect in diagnosing endometriosis, fills the gap in the existing diagnosis technology of endometriosis, and solves the problems that need to be solved in the diagnosis of the disease.
[0078] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that they can still modify or replace the technical solution of the present invention with equivalents, and these modifications or equivalent replacements cannot cause the modified technical solution to deviate from the spirit and scope of the technical solution of the present invention.
Claims
1. A method for preparing a silver / silver sulfide nanoprobe for dual diagnosis of endometriosis, characterized in that: The steps include: S1. Prepare silver / silver sulfide Ag / Ag2S-PEI using silver acetylacetonate and polyethyleneimine as raw materials; S2, grafting retinoic acid onto the Ag / Ag2S-PEI prepared in step S1 to prepare a silver / silver sulfide-retinoic acid preparation Ag / Ag2S-RA; S3, chelating manganese ions onto the Ag / Ag2S-RA prepared in step S2 to prepare a silver / silver sulfide-retinoic acid chelated manganese ion preparation Ag / Ag2S-Mn@RA; S4. Grafting 4-mercaptobenzoic acid onto the Ag / Ag2S-Mn@RA prepared in step S3 to prepare the silver / silver sulfide nanoprobe Ag / Ag2S-Mn@RA-4-MBA.
2. The method for preparing a silver / silver sulfide nanoprobe for dual diagnosis of endometriosis according to claim 1, characterized in that: In step S1, the steps of preparing Ag / Ag2S-PEI include: S1-1, prepare solution A according to the ratio of silver acetylacetonate: trisodium citrate: ethylene glycol = 0.6 mmol: 0.2 mmol: 20 mL; 150 mg of polyethyleneimine was added to solution A, and the mixture was reacted for 120 min at room temperature and 800 rpm magnetic stirring to obtain solution B; S1-2, adding 1.5 mL of 0.05 M thioacetamide to solution B, reacting for 5 min at room temperature and 800 rpm under magnetic stirring to obtain solution C; adding triethanolamine to solution C, reacting for 5 min at room temperature and 800 rpm under magnetic stirring; S1-3. After the reaction is completed, the product is transferred to a microwave synthesizer and maintained at 200°C for 1 hour. The precipitate is then collected by low-temperature centrifugation at 14,000 rpm, 10 min, and 4°C. The precipitate is washed three times with pure water. Finally, the product is dispersed in pure water to obtain Ag / Ag2S-PEI.
3. The method for preparing a silver / silver sulfide nanoprobe for dual diagnosis of endometriosis according to claim 2, characterized in that: The volume ratio of solution A: thioacetamide: triethanolamine is 4: 0.3: 0.
1.
4. The method for preparing a silver / silver sulfide nanoprobe for dual diagnosis of endometriosis according to claim 1, characterized in that: In step S2, the steps of preparing the silver / silver sulfide-retinoic acid preparation Ag / Ag2S-RA include: S2-1, mix retinoic acid and ethanol at a mass volume ratio of 1 mg: 1 mL, add EDC and NHS, and activate at 37°C on a shaker for 1 h; S2-2, dissolving the Ag / Ag2S-PEI prepared in step S1 and the solution activated in step S2-1 in anhydrous ethanol at a mass ratio of 5:1, and stirring in an ice bath for 2 h; After stirring, the precipitate was collected by centrifugation at 14000 rpm for 10 min, and the precipitate was washed twice with anhydrous ethanol. The final product was dispersed in anhydrous ethanol to obtain Ag / Ag2S-RA.
5. The method for preparing a silver / silver sulfide nanoprobe for dual diagnosis of endometriosis according to claim 4, characterized in that: In step S2-1, the mass ratio of retinoic acid:EDC:NHS is 1:4:
4.
6. The method for preparing a silver / silver sulfide nanoprobe for dual diagnosis of endometriosis according to claim 1, characterized in that: In step S3, the preparation of Ag / Ag2S-Mn@RA includes the following steps: S3-1, according to step S2, prepare Ag / Ag2S-RA∶SH-PEG-NH2∶water=1mg∶1mg∶1mL, mix and stir for 6h, and obtain Ag / Ag2S-RA-PEG-NH2 after centrifugation; S3-2, re-disperse Ag / Ag2S-RA-PEG-NH2 in water, the pH of the Ag / Ag2S-RA-PEG-NH2 aqueous solution is not less than 7.4; add DOTA-NHS to react for 30 minutes; add MnCl2 and stir to react for 12 hours; S3-3. After the reaction is completed, the precipitate is collected by centrifugation at 14000 rpm for 10 min, and the precipitate is washed twice with pure water. The final product is dispersed in pure water to obtain Ag / Ag2S-Mn@RA.
7. The method for preparing a silver / silver sulfide nanoprobe for dual diagnosis of endometriosis according to claim 6, characterized in that: In step S3-2, the mass ratio of DOTA-NHS:MnCl2 is 1:0.
2.
8. The method for preparing a silver / silver sulfide nanoprobe for dual diagnosis of endometriosis according to claim 1, characterized in that: The preparation of silver / silver sulfide nanoprobes includes: dispersing Ag / Ag2S-Mn@RA and 4-mercaptobenzoic acid in anhydrous ethanol according to the mass volume ratio of Ag / Ag2S-Mn@RA:4-mercaptobenzoic acid:anhydrous ethanol prepared in step S3 at a ratio of 0.4 mg:2.18 mg:4 mL, stirring for 12 hours, and centrifuging to obtain Ag / Ag2S-Mn@RA-4-MBA.
9. A silver / silver sulfide nanoprobe prepared by the method for preparing a silver / silver sulfide nanoprobe for dual diagnosis of endometriosis as claimed in any one of claims 1 to 8.
10. A use of the silver / silver sulfide nanoprobe as claimed in claim 9, characterized in that: Application of silver / silver sulfide nanoprobes in magnetic resonance / Raman dual diagnosis of endometriosis for non-medical purposes.
Citation Information
Patent Citations
Ag / Ag2S Janus heterojunction synthesized by one-step method and application of Ag / Ag2S Janus heterojunction
CN116890119A
Near-IR emitting cationic silver chalcogenide quantum dots
US20170152435A1
